Bare Financial Services’s Vir Biotechnology VIR Stock Holding History

Bare Financial Services’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$869	Hold	97	–	–	﹤0.01%	1313
2025 Q4	$585	Hold	97	–	–	﹤0.01%	1315
2025 Q3	$554	Buy	+97	New	+$496	﹤0.01%	1232

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Bare Financial Services's VIR Position: Q1 2026 in Review

Bare Financial Services held its Vir Biotechnology (VIR) position steady in Q1 2026 at 97 shares worth $869. The position accounts for ﹤0.01% of the portfolio, ranked #1313.

Bare Financial Services first reported a position in VIR in Q3 2025 and has held it in 3 quarters since. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

Bare Financial Services held 97 shares of Vir Biotechnology worth $869 as of Q1 2026.
Bare Financial Services left its Vir Biotechnology share count unchanged in Q1 2026.
Vir Biotechnology made up ﹤0.01% of Bare Financial Services's portfolio in Q1 2026, its #1313 holding.
Bare Financial Services first reported a position in Vir Biotechnology in Q3 2025 and has held it in 3 quarters since.
251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Bare Financial Services's 13F filing for Q1 2026, filed 14 May 2026.